Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-03-10
2000-08-08
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31417
Patent
active
061002860
ABSTRACT:
The invention is directed to improved methods for modulating the human sexual response by administering an oral formulation of phentolamine to the blood circulation thereby modulating the sexual response on demand.
REFERENCES:
patent: 2503059 (1950-04-01), Miescher et al.
patent: 3937834 (1976-02-01), Hunger et al.
patent: 3943246 (1976-03-01), Sturmer
patent: 4127118 (1978-11-01), Latorre
patent: 4139617 (1979-02-01), Grunwell et al.
patent: 4530920 (1985-07-01), Nestor et al.
patent: 4801587 (1989-01-01), Voss et al.
patent: 4863911 (1989-09-01), Anderson, Jr. et al.
patent: 4885173 (1989-12-01), Stanley et al.
patent: 5059603 (1991-10-01), Rubin
patent: 5065744 (1991-11-01), Zusmanovsky
patent: 5079018 (1992-01-01), Ecanow
patent: 5145852 (1992-09-01), Virag
patent: 5236904 (1993-08-01), Gerstenberg et al.
patent: 5256652 (1993-10-01), El-Rashidy
patent: 5270323 (1993-12-01), Milne, Jr. et al.
patent: 5298261 (1994-03-01), Pebley et al.
patent: 5399581 (1995-03-01), Laragh et al.
patent: 5565466 (1996-10-01), Zorgniotti et al.
patent: 5731339 (1998-03-01), Lowrey
AC-Di-Sol.RTM., Croscarmellose Sodium, NF (Accelerates DisSolution) (Product Description Brochure); FMC Corporation, Philadelphia, PA (1988).
Althof et al., "Sexual, psychological, and marital impact of self-injection of papaverine and phentolamine: a long-term prospective study," J. Sex & Marital Ther., 17(2):101-112 (1991).
Azadzoi et al., "Effects of Intracavernosal Trazadone Hydrochloride: Animal and Human Stuides," J. Urol., 144(5):1277-1282 (1990).
Barnett and Fowler, "The Action Of "Regitine" In Man With Special Reference To Its Adrenergic Blocking Action," Australasian Anals of Medicine, 1:109-119 (1952).
Brindley, G.S., "Cavernosal alpha-blockade and human penile erection," J. Physiol., 342:24P (1983).
Brindley, G.S., "Cavernosal Alpha-Blockade: A New Technique for Investigating and Treating Erectile Impotence," Brit. J. Psychiat., 143:332-337 (1983).
Brindley, G.S., "Pilot experiments on the actions of drugs injected into the human corpus cavernosum penis," Br. J. Pharmac., 87:495-500 (1986).
Corriere, Jr. et al., "Development of Fibrotic Penile Lesions Secondary to the Intracorporeal Injection of Vasoactive Agents," J. Urol., 140:615-617 (1988).
Dawson et al., "The Transient Anti-Hypertensive Effect of Phentolamine in Patients Receiving Beta-Blocker Treatment," J. Int. Med. Res., 5:462-464 (1977).
Diedrichs et al., "Reduction of Sympathetic Influence on Penile Erection by Phentolamine," Ural. Int., 46:64-66 (1991).
Georgopoulos et al., "Treatment of Chronic Heart Failure with Slow Release Phentolamine," Europ. J. Clin. Pharmacol., 13:325-329 (1978).
Godbillion et al., "Determination of the Major Metabolite pf Phentolamine in Human Plasma And Urine By High-Performance Liquid Chromatography," J. Chrom., 222:461-466 (1981).
Gould et al., "Oral Therapy with Phetolamine in Chronic Congestive Heart Failure," Chest, 75(4):487-491 (Apr. 4, 1979).
Gwinup, G., "Oral Phentolamine in Nonspecific Erectile Insufficiency," Ann. Int. Med., Jul. 15, 1988, 162-163.
Imhof et al., "Human Pharmacology of Orally Administered Phentolamine," In: Phentolamine in Heart Failure and Other Cardiac Disorders, Taylor, S.H., and Gould, L.A., (eds.), Ben Huber, pp. 11-22 (1976).
Larsen et al., "Fibrosis of Corpus Cavernosum after Intracavernous Injection of Phentolamine/Papaverine," J. Urol., 137:292-293 (1987).
Marriot, H.J.L., "An Alarming Pressor Reaction To Regitine," 46(5):1001-1002 (May, 1957).
McDonnell, S.M. et al., "Imipramine-induced erection, masturbation, and ejaculation in male horses," Pharmacol. Biochem. Behav. (USA), 27(1):187-191 (May, 1987) (Abstract).
Montorsie et al., "Clinical Reliability of Multi-Drug Intracavernous Vasoactive Pharmacotherapy for Diabetic Impotence," Acta Diabetol., 31:1-5 (1994).
Pfister et al., "Estimation of the Plasma Concentration and Course of Action of Phentol-amine Based On Its Inhibitory Effect On Adrenaline-Induced Platelet Aggregation," Br. J. Clin. Pharmac., 5:175-180 (1978).
Phyicians' Desk Reference, 37 Edition, p. 409 and 864 (1983).
Ruskin, J.N. et al., "Primary Pulmonary Hypertension Treated With Oral Phentolamine," Annals of Internal Medicine, 90:772-774 (1979).
Schreiber, R. et al., "Hemodynamic Improvement following a Single Dose of Oral Phentolamine: Administration in Patients with Chronic Low Output Cardiac Failure," Chest, 76(5):571-575 (Nov., 1979).
Selvaag, O. et al., "Experiences with Regitin (A New Vasodilator Compound)," Acta Medica Scandinavica, vol. CXLVI, fase. III, pp. 209-215 (1953).
Sioufi, A. et al., "Gas Chromatographic Determination of Phenentolamine (Regitine) in Human Plasma and Urine," Journal of Chromatography, 222:429-435 (1981).
Sonda et al., "The Role of Yohimbine for the Treatment of Erectile Impotence," J. Sex & Marital Ther., 16(1):15-21 (1990).
The Extra Pharmacopoeia: The authoritative reference work on drugs and medicines in current use, Twenty-sixth Edition, 2 pages (1988).
Trapold, J.H. et al., "Pharmacological and Toxicological Studies on 2-(N-p'tolyl-N-(m'-Hydroxypheyl)-Aminomethyl)-Imidazoline (C-7337), A New Adrenergic Blocking Agent," pp. 119-127 (1950).
United States Pharmacopeia, Twentieth Revision, Official from Jul. 1, 1980, The National Formulary, Fifteenth Edition, Official from Jul. 1, 1980, United States Pharmacopeial Convention, Inc., Rockville, Maryland, pp. 615-617 (1979).
Virag, R., "Intracavernous Injection of Papaverine for Erectile Failure," Lancet, ii:938 (1982).
Virag et al., "Intracavernous Injection of Papaverine as a Diagnostic and Therapeutic Method in Erectile Failure," Angiology, 35:79-87 (1984).
Wagner, G. et al., "Buccal Phentolamine-A pilot trial for male erectile dysfunction at three separate clinics," Int. J. Impotence Res., 6(Suppl. I):D78 (1994).
Williams, Textbook of Endocrinology, p. 313 (Circa, 1976).
Zorgniotti, A. W., ""On Demand" Oral Drug For Erection In Impotent Men," J. Urology (AUA Eighty-Seventh Annual Meeting May 10-14, 1992), 147(4)(Suppl.):308A (Apr., 1992) (Abstract 382).
Zorgniotti, A.W., "Experience with buccal phentolamine mesylate for impotence," International Journal of Impotence Research, 6(1):37-41 (Mar. 1994).
Zorgniotti et al., "Auto-Injection of the Corpus Cavernosum with a Vasoactive Drug Combination for Vasculogenic Impotence", J. Urol., 133:39-41 (1985).
Beavo, J.A. et al., In: Advances in Second Messenger and Phosphoprotein Research, Greengard et al., (eds.), vol. 22, pp. 1-38 (1988).
Biotechnology Newswatch, "Nice try, but no Viagra, say experts reviewing new potency pills," pp. 4-5 (Jun., 1998).
Gissinger, D. et al., "A Comparative Evaluation of the Properties of some Tablet Disintegrant," Drug Development and Industrial Pharmacy, 6(5):511-536 (1980).
NIH Consensus Conference, "Impotence," NIH Consensus Development Panel on Impotence, Journal American Medical Association, 270(1):83-90 (1993).
Terrett, N.K. et al., "Sildenafil (Viagra.TM.), A Potent and Selective Inhibitor of Type 5 cGMP Phosphodiesterase with Utility for the Treatment of Male Erectile Dysfunction," Bioorganic & Medicinal Chemistry Letters, 6(15):1819-1824 (1996).
ABPI Data Sheet Compendium, pp. 186-187 (1976).
ABPI Data Sheet Compendium, pp. 186-189 (1977).
Becker, A.J. et al., "Oral Phentolamine as Treatment for Erectile Dysfunction," The Journal of Urology, 159:1214-1216 (1998).
British Pharmaceutical Codex 1954, London, The Pharmaceutical Press, 17 Bloomsbury Square WCI, pp. 572-575.
British Pharmaceutical Codex 1959, London, The Pharmaceutical Press, 17 Bloomsbury Square WCI, pp. 562-565.
British Pharmaceutical Codex 1968, London, The Pharmaceutical Press, 17 Bloomsbury Square WCI, pp. xxiv-xxvii and 616-619.
British Pharmaceutical Codex 1973, London, The Pharmaceutical Press, 17 Bloomsbury Square WCIA 2NN, pp. 373-374.
British Pharmacopceia 1963, The Pharmaceutical Press 17 Bloomsbury Square London WCI, pp. 600-603.
British Pharmacopceia 1968, The Pharmaceutical Press 17 Bloomsbury Square London WCI, pp. 758-761.
British Pharmacopceia 1973, London Her Majesty's Stationary Office 1973, p. 364.
British Pharmacop
Spivack Phyllis G.
Zonagen, Inc.
LandOfFree
Methods and formulations for modulating the human sexual respons does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and formulations for modulating the human sexual respons, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and formulations for modulating the human sexual respons will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1150577